TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Stock
Certificat
DE000SH6Y8W4
| Market Closed - Deutsche Boerse AG 15:39:06 2024-06-26 EDT | ||
| 1.9 EUR | +0.53% |
|
| Current month | +10.47% | ||
| 1 month | +9.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 1.9 | +0.53% |
| 24-06-25 | 1.89 | -0.53% |
| 24-06-24 | 1.9 | +1.60% |
| 24-06-21 | 1.87 | 0.00% |
| 24-06-20 | 1.87 | +3.89% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 03:39 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SH6Y8W |
| ISIN | DE000SH6Y8W4 |
| Date issued | 2022-05-10 |
| Strike | 273.1 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2 € |
|---|---|
| Lowest since issue | 0.11 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
